Cequa is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 5 US drug patents filed from 2018 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 28, 2037. Details of Cequa's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11951153 | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(12 years from now) | Active |
| US10918694 | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(12 years from now) | Active |
| US8980839 | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof |
Aug, 2033
(8 years from now) | Active |
| US9937225 | Topical formulations and uses thereof |
Aug, 2033
(8 years from now) | Active |
| US10441630 | Topical formulations and uses thereof |
Aug, 2033
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cequa's patents.
Latest Legal Activities on Cequa's Patents
Given below is the list of recent legal activities going on the following patents of Cequa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Electronic Review Critical | 07 Jun, 2024 | US11951153 |
| Patent eGrant Notification | 09 Apr, 2024 | US11951153 |
| Recordation of Patent Grant Mailed Critical | 09 Apr, 2024 | US11951153 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951153 |
| Email Notification Critical | 09 Apr, 2024 | US11951153 |
| Mail Patent eGrant Notification | 09 Apr, 2024 | US11951153 |
| Patent Issue Date Used in PTA Calculation Critical | 09 Apr, 2024 | US11951153 |
| Email Notification Critical | 21 Mar, 2024 | US11951153 |
| Issue Notification Mailed Critical | 20 Mar, 2024 | US11951153 |
| Email Notification Critical | 07 Mar, 2024 | US11951153 |
US patents provide insights into the exclusivity only within the United States, but Cequa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cequa's family patents as well as insights into ongoing legal events on those patents.
Cequa's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Cequa:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Cequa(Cyclosporine) has 1 clinical trial that has been verified in 2024.
Generic Launch
Generic Release Date:
Cequa's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 28, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cequa Generic API suppliers:
Cyclosporine is the generic name for the brand Cequa. 14 different companies have already filed for the generic of Cequa, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cequa's generic
Alternative Brands for Cequa
Cequa which is used for increasing tear production in patients with dry eye (keratoconjunctivitis sicca)., has several other brand drugs in the same treatment category and using the same active ingredient (Cyclosporine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Harrow Eye |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Cyclosporine. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Cyclosporine, Cequa's active ingredient. Check the complete list of approved generic manufacturers for Cequa
About Cequa
Cequa is a drug owned by Sun Pharmaceutical Industries Ltd. It is used for increasing tear production in patients with dry eye (keratoconjunctivitis sicca). Cequa uses Cyclosporine as an active ingredient. Cequa was launched by Sun Pharm in 2018.
Approval Date:
Cequa was approved by FDA for market use on 14 August, 2018.
Active Ingredient:
Cequa uses Cyclosporine as the active ingredient. Check out other Drugs and Companies using Cyclosporine ingredient
Treatment:
Cequa is used for increasing tear production in patients with dry eye (keratoconjunctivitis sicca).
Dosage:
Cequa is available in solution form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.09% | SOLUTION | Prescription | OPHTHALMIC |